BR112022014925A8 - Inibidores macrocíclicos de rip2-quinase - Google Patents

Inibidores macrocíclicos de rip2-quinase

Info

Publication number
BR112022014925A8
BR112022014925A8 BR112022014925A BR112022014925A BR112022014925A8 BR 112022014925 A8 BR112022014925 A8 BR 112022014925A8 BR 112022014925 A BR112022014925 A BR 112022014925A BR 112022014925 A BR112022014925 A BR 112022014925A BR 112022014925 A8 BR112022014925 A8 BR 112022014925A8
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
rip2
macrocyclic
compounds
kinase
Prior art date
Application number
BR112022014925A
Other languages
English (en)
Other versions
BR112022014925A2 (pt
BR112022014925B1 (pt
Inventor
Lamotte Yann
Dodic Nérina
Tap Aurélien
Denis Alexis
Brusq Jean-Marie
Daoubi Khamlichi Mourad
André René Benderitter Pascal
Original Assignee
Oncodesign Sa
Oncodesign Prec Medicine Opm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncodesign Sa, Oncodesign Prec Medicine Opm filed Critical Oncodesign Sa
Publication of BR112022014925A2 publication Critical patent/BR112022014925A2/pt
Publication of BR112022014925A8 publication Critical patent/BR112022014925A8/pt
Publication of BR112022014925B1 publication Critical patent/BR112022014925B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0834Compounds having one or more O-Si linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INIBIDORES MACROCÍCLICOS DE RIP2-QUINASE. A presente invenção refere-se a compostos macrocíclicos e a composições contendo os ditos compostos que atuam como inibidores de quinase, em particular como inibidores de RIP2-quinase, e/ou mutantes da mesma, para uso no diagnóstico, na prevenção e/ou no tratamento de doenças associadas à RIP2-quinase. Além disso, a presente invenção refere-se a métodos de uso dos ditos compostos, por exemplo, como medicamento ou agente de diagnóstico.
BR112022014925-5A 2020-01-31 2021-02-01 Inibidores macrocíclicos de rip2-quinase, seus usos, e composição farmacêutica BR112022014925B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20154852.6 2020-01-31
EP20154852 2020-01-31
PCT/EP2021/052255 WO2021152165A1 (en) 2020-01-31 2021-02-01 Macrocyclic rip2-kinase inhibitors

Publications (3)

Publication Number Publication Date
BR112022014925A2 BR112022014925A2 (pt) 2022-09-20
BR112022014925A8 true BR112022014925A8 (pt) 2023-05-09
BR112022014925B1 BR112022014925B1 (pt) 2023-12-19

Family

ID=69423151

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014925-5A BR112022014925B1 (pt) 2020-01-31 2021-02-01 Inibidores macrocíclicos de rip2-quinase, seus usos, e composição farmacêutica

Country Status (14)

Country Link
US (1) US20230126352A1 (pt)
EP (1) EP4097110A1 (pt)
JP (1) JP2023516551A (pt)
KR (1) KR20230005117A (pt)
CN (1) CN115698020A (pt)
AR (1) AR124556A1 (pt)
AU (1) AU2021214866A1 (pt)
BR (1) BR112022014925B1 (pt)
CA (1) CA3168814A1 (pt)
IL (1) IL295196A (pt)
MX (1) MX2022009285A (pt)
TW (1) TW202140499A (pt)
UY (1) UY39061A (pt)
WO (1) WO2021152165A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874221A (zh) * 2022-05-12 2022-08-09 广州佳途科技股份有限公司 一种rip2激酶抑制剂中间体及其合成方法
WO2024099363A1 (zh) * 2022-11-09 2024-05-16 宁波康柏睿格医药科技有限公司 Rip2抑制剂联合免疫检查点抑制剂药物组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150129016A (ko) * 2013-03-15 2015-11-18 입센 파마 에스.에이.에스 마크로시클릭 lrrk2 키나제 억제제
BR112015022650A8 (pt) * 2013-03-15 2018-01-23 Oncodesign Sa inibidores de quinase induzível por sal macrocíclico.
MX2015012526A (es) * 2013-03-15 2016-04-26 Oncodesign Sa Inhibodores macrociclicos de cinasa rip2.
WO2015136073A1 (en) * 2014-03-14 2015-09-17 Oncodesign Sa Macrocyclic tgf-br2 kinase inhibitors
CN107108641A (zh) * 2014-09-17 2017-08-29 昂科迪塞恩股份有限公司 大环lrrk2激酶抑制剂
WO2016042087A1 (en) 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic rip2 kinase inhibitors

Also Published As

Publication number Publication date
BR112022014925A2 (pt) 2022-09-20
TW202140499A (zh) 2021-11-01
AU2021214866A1 (en) 2022-09-22
CA3168814A1 (en) 2021-08-05
WO2021152165A1 (en) 2021-08-05
IL295196A (en) 2022-09-01
MX2022009285A (es) 2022-11-09
JP2023516551A (ja) 2023-04-20
UY39061A (es) 2022-01-31
AR124556A1 (es) 2023-04-12
BR112022014925B1 (pt) 2023-12-19
EP4097110A1 (en) 2022-12-07
CN115698020A (zh) 2023-02-03
US20230126352A1 (en) 2023-04-27
KR20230005117A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112019000598A2 (pt) rna para terapia de câncer
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112022014925A8 (pt) Inibidores macrocíclicos de rip2-quinase
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112018076485A8 (pt) Carotenoides microbianos afetando a composição microbiana do intestino
BR112017005299A2 (pt) inibidores de lrrk2 cinase macrocíclicos
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
BR112017004035A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112022014456A2 (pt) Tafoxiparina para o tratamento da pré-eclâmpsia

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ONCODESIGN PRECISION MEDICINE (OPM) (FR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2021, OBSERVADAS AS CONDICOES LEGAIS